Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.

Brian Michael Alexander; Manmeet Singh Ahluwalia; Arati Suvas Desai; Jorg Dietrich; Thomas Joseph Kaley; David M. Peereboom; Naoko Takebe; Jeffrey G. Supko; Serena Desideri; Joy D. Fisher; Megan Sims; Xiaobu Ye; Louis B. Nabors; Stuart A. Grossman; Patrick Y. Wen

doi:10.1200/JCO.2017.35.15_SUPPL.2005

Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.

Brian Michael Alexander
, Manmeet Singh Ahluwalia
, Arati Suvas Desai
, Jorg Dietrich
, Thomas Joseph Kaley
, David M. Peereboom
, Naoko Takebe
, Jeffrey G. Supko
, Serena Desideri
, Joy D. Fisher
, Megan Sims
, Xiaobu Ye
, Louis B. Nabors
, Stuart A. Grossman
, Patrick Y. Wen

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1200/JCO.2017.35.15_SUPPL.2005
State	Published - May 30 2017
Event	Journal of Clinical Oncology - Duration: Jan 1 2020 → …

Conference

Conference	Journal of Clinical Oncology
Period	1/1/20 → …

Disciplines

Medicine and Health Sciences
Oncology
Pathology
Internal Medicine

Access to Document

10.1200/JCO.2017.35.15_SUPPL.2005License: Unspecified

Cite this

Alexander, B. M., Ahluwalia, M. S., Desai, A. S., Dietrich, J., Kaley, T. J., Peereboom, D. M., Takebe, N., Supko, J. G., Desideri, S., Fisher, J. D., Sims, M., Ye, X., Nabors, L. B., Grossman, S. A., & Wen, P. Y. (2017). Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2017.35.15_SUPPL.2005

Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM. / Alexander, Brian Michael; Ahluwalia, Manmeet Singh; Desai, Arati Suvas et al.
2017. Journal of Clinical Oncology.

Research output: Contribution to conference › Presentation

Alexander, BM, Ahluwalia, MS, Desai, AS, Dietrich, J, Kaley, TJ, Peereboom, DM, Takebe, N, Supko, JG, Desideri, S, Fisher, JD, Sims, M, Ye, X, Nabors, LB, Grossman, SA & Wen, PY 2017, 'Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.', Journal of Clinical Oncology, 1/1/20. https://doi.org/10.1200/JCO.2017.35.15_SUPPL.2005

Alexander BM, Ahluwalia MS, Desai AS, Dietrich J, Kaley TJ, Peereboom DM et al.. Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. 2017. Journal of Clinical Oncology. doi: 10.1200/JCO.2017.35.15_SUPPL.2005

@conference{962d9b2d4e264132b427bf74544e3e3d,

title = "Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.",

author = "Alexander, \{Brian Michael\} and Ahluwalia, \{Manmeet Singh\} and Desai, \{Arati Suvas\} and Jorg Dietrich and Kaley, \{Thomas Joseph\} and Peereboom, \{David M.\} and Naoko Takebe and Supko, \{Jeffrey G.\} and Serena Desideri and Fisher, \{Joy D.\} and Megan Sims and Xiaobu Ye and Nabors, \{Louis B.\} and Grossman, \{Stuart A.\} and Wen, \{Patrick Y.\}",

note = "2005 Background: The standard of care treatment for newly diagnosed GBM is maximal safe surgical resection followed by two DNA damaging agents, RT and TMZ. Cellular response to DNA damage involves checkpoints that halt the cell cycle to allow DNA repair.; Journal of Clinical Oncology ; Conference date: 01-01-2020",

year = "2017",

month = may,

day = "30",

doi = "10.1200/JCO.2017.35.15\_SUPPL.2005",

language = "American English",

}

TY - CONF

T1 - Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.

AU - Alexander, Brian Michael

AU - Ahluwalia, Manmeet Singh

AU - Desai, Arati Suvas

AU - Dietrich, Jorg

AU - Kaley, Thomas Joseph

AU - Peereboom, David M.

AU - Takebe, Naoko

AU - Supko, Jeffrey G.

AU - Desideri, Serena

AU - Fisher, Joy D.

AU - Sims, Megan

AU - Ye, Xiaobu

AU - Nabors, Louis B.

AU - Grossman, Stuart A.

AU - Wen, Patrick Y.

N1 - 2005 Background: The standard of care treatment for newly diagnosed GBM is maximal safe surgical resection followed by two DNA damaging agents, RT and TMZ. Cellular response to DNA damage involves checkpoints that halt the cell cycle to allow DNA repair.

PY - 2017/5/30

Y1 - 2017/5/30

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2005

U2 - 10.1200/JCO.2017.35.15_SUPPL.2005

DO - 10.1200/JCO.2017.35.15_SUPPL.2005

M3 - Presentation

T2 - Journal of Clinical Oncology

Y2 - 1 January 2020

ER -

Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.

Conference

Disciplines

Access to Document

Other files and links

Cite this